Aberdeen Group plc Sells 664,801 Shares of Pfizer Inc. $PFE

Aberdeen Group plc lessened its position in Pfizer Inc. (NYSE:PFE) by 11.3% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 5,205,453 shares of the biopharmaceutical company’s stock after selling 664,801 shares during the period. Aberdeen Group plc owned approximately 0.09% of Pfizer worth $129,616,000 as of its most recent filing with the SEC.

Other hedge funds also recently bought and sold shares of the company. Horizon Financial Services LLC grew its stake in Pfizer by 174.8% in the fourth quarter. Horizon Financial Services LLC now owns 1,014 shares of the biopharmaceutical company’s stock valued at $25,000 after acquiring an additional 645 shares during the period. Grey Fox Wealth Advisors LLC bought a new position in shares of Pfizer during the 3rd quarter valued at about $29,000. Howard Hughes Medical Institute acquired a new position in shares of Pfizer in the 2nd quarter valued at approximately $30,000. Darwin Wealth Management LLC bought a new stake in Pfizer during the 2nd quarter worth approximately $32,000. Finally, True Wealth Design LLC raised its holdings in Pfizer by 302.5% during the 3rd quarter. True Wealth Design LLC now owns 1,296 shares of the biopharmaceutical company’s stock worth $33,000 after buying an additional 974 shares during the period. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

PFE has been the subject of several research reports. Royal Bank Of Canada assumed coverage on shares of Pfizer in a research report on Tuesday, February 24th. They set an “underperform” rating and a $25.00 price objective for the company. Zacks Research raised shares of Pfizer from a “strong sell” rating to a “hold” rating in a research note on Tuesday, February 24th. Argus raised Pfizer from a “hold” rating to a “buy” rating and set a $35.00 price target on the stock in a research note on Monday, March 2nd. Morgan Stanley set a $27.00 price target on Pfizer and gave the company a “positive” rating in a report on Tuesday, March 17th. Finally, Cantor Fitzgerald reissued a “neutral” rating and issued a $27.00 target price on shares of Pfizer in a research report on Wednesday, February 4th. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, thirteen have assigned a Hold rating and three have given a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $28.19.

Pfizer Stock Down 0.6%

Pfizer stock opened at $28.37 on Friday. The company has a current ratio of 1.16, a quick ratio of 0.87 and a debt-to-equity ratio of 0.71. Pfizer Inc. has a 1-year low of $20.92 and a 1-year high of $28.75. The company has a fifty day simple moving average of $27.03 and a 200 day simple moving average of $25.79. The company has a market cap of $161.29 billion, a P/E ratio of 20.86 and a beta of 0.43.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 EPS for the quarter, topping the consensus estimate of $0.57 by $0.09. Pfizer had a net margin of 12.42% and a return on equity of 20.48%. The firm had revenue of $17.56 billion for the quarter, compared to analysts’ expectations of $16.93 billion. During the same period in the previous year, the firm posted $0.63 EPS. The company’s revenue for the quarter was down 1.2% on a year-over-year basis. Research analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer News Summary

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Belgian court orders Poland and Romania to accept €1.9B ($2.2B) of Pfizer COVID-19 vaccine deliveries — a material recognized/near‑term revenue win that supports sales visibility. Belgian court orders Poland, Romania to buy $2.2 billion of Pfizer COVID vaccines
• Positive Sentiment: England offered Pfizer’s RSV vaccine to an additional ~3 million older adults — a rollout expansion that could lift recurring vaccine revenue in key markets. Pfizer RSV vaccine offered to 3M more older adults in England
• Positive Sentiment: Technicals and sentiment remain constructive in parts of the market — commentary notes PFE trading above its 50- and 200-day SMAs and outpacing peers at times, which can support short‑term buying interest. PFE Stock Trades Above 200 & 50-Day SMA for 3 Months
• Neutral Sentiment: Pfizer is closing its South San Francisco research site to cut costs and concentrate R&D investments — could boost near‑term margins but raises questions about long‑term pipeline capacity. Pfizer Site Closure Puts Cost Focus And R&D Productivity In Spotlight
• Neutral Sentiment: Corporate reshaping: Pfizer exits part of the ViiV HIV venture as partners adjust ownership — reduces direct HIV exposure but simplifies portfolio. GSK and Shionogi Reshape ViiV Healthcare Ownership as Pfizer Exits HIV Venture
• Neutral Sentiment: Investor pieces on valuation and options (covered-call strategies) highlight yield attraction but offer no company‑level catalyst — useful for income investors but neutral for PFE’s share direction. Boost Pfizer’s Already Hefty 6% Dividend Yield With A Covered Call
• Negative Sentiment: U.S. policy risk: the Trump administration proposed tariffs up to 100% on branded drugs — unless makers agree to U.S. pricing deals or on‑shore manufacturing commitments — creating large downside regulatory risk for branded drug revenue and margins. Trump Administration Unveils Up to 100% Tariff on Branded Drugs
• Negative Sentiment: Clinical/program execution concerns: Pfizer and BioNTech paused recruitment for a U.S. trial of an updated COVID vaccine due to low enrollment — signals demand softness for new COVID boosters and complicates future vaccine growth. Pfizer, BioNTech halt US COVID vaccine study after recruitment struggles
• Negative Sentiment: Analyst/watchdog skepticism: commentary argues Pfizer’s large dividend may mask slower organic growth, keeping some investors cautious about forward earnings momentum. Bearish on Pfizer (PFE) as Big Dividend Fails to Mask the Growth Problem

Pfizer Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.